Sentante Receives CE Mark Approval for Endovascular Robotic Platform

Sentante has announced it has secured CE mark approval for its flagship device, marking a major transition from research and development to full commercial readiness.

The certification enables Sentante to begin marketing and selling its multi-domain robotic platform technology across European markets, following a period of intensive development and regulatory validation.

This milestone reflects the company’s progress over recent months in successfully navigating complex regulatory pathways, bringing its product from concept through to a clinically validated, market-ready solution.

“This is a defining moment for Sentante,” said Edvardas Satkauskas, CEO and co-founder of Sentante. “Achieving CE mark is not only a validation of our technology, but also of the rigorous work undertaken by our team to meet the highest regulatory standards. We are now positioned to move decisively into commercialisation and begin delivering real impact for clinicians and patients.”

Sentante’s device is designed to support endavascular procedures with enhanced precision and control, addressing critical needs in and redefining endovascular intervention procedures. With CE mark approval, the company can now partner with hospitals and healthcare providers across Europe to integrate the technology into routine clinical practice.

The approval follows a series of regulatory milestones achieved over the past months, underscoring the robustness of Sentante’s development programme and its commitment to safety, efficacy, and quality.

“Transitioning from an R&D-focused organisation to a commercial-stage company is a significant step,” added Dr. Tomas Baltrunas, co-founder of Sentante.“We have built the foundations not only to launch successfully, but to scale — ensuring that our innovation reaches the patients who need it most.”

Sentante will now focus on initial market rollout, clinician training, and expanding its commercial footprint, while continuing to advance its product pipeline.

Sentante recently unveiled its digital indeflator, a precision-controlled system that replaces the traditional manual indeflator used in endovascular procedures such as angioplasty and stent deployment.

Source: Sentante

The post Sentante Receives CE Mark Approval for Endovascular Robotic Platform appeared first on Surgical Robotics Technology.